ASC41
id:
asc41-0-4709729
title:
ASC41
text:
ASC41 is a thyromimetic prodrug metabolized in the liver by CYP3A4 to an active form, ASC41-A, that is selective for thyroid hormone receptor beta. It is developed for non-alcoholic fatty liver disease. In 2023, Viking Therapeutics filed a lawsuit against ASC41's developer, Chinese company Ascletis BioScience, accusing it of stealing Viking's trade secrets to develop ASC41 which is allegedly similar to VK2809.
brand slug:
wiki
category slug:
encyclopedia
description:
original url:
https://en.wikipedia.org/wiki/ASC41
date created:
date modified:
2023-12-02T21:43:30Z
main entity:
{"identifier":"Q123875571","url":"https://www.wikidata.org/entity/Q123875571"}
image:
fields total:
13
integrity:
13